Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $430.6 million.

  • Janux Therapeutics' Cash & Equivalents rose 80.87% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 80.87%. This contributed to the annual value of $430.6 million for FY2024, which is 2142.15% up from last year.
  • Latest data reveals that Janux Therapeutics reported Cash & Equivalents of $430.6 million as of FY2024, which was up 2,142.15% from $19.2 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Cash & Equivalents ranged from a high of $430.6 million in FY2024 and a low of $7.8 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $51.4 million (2022), whereas its average is $167.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 62.66% in 2023, then soared by 2,142.15% in 2024.
  • Yearly analysis of 5 years shows Janux Therapeutics' Cash & Equivalents stood at $7.8 million in 2020, then surged by 355.42% to $35.6 million in 2021, then skyrocketed by 44.53% to $51.4 million in 2022, then slumped by 62.66% to $19.2 million in 2023, then spiked by 2,142.15% to $430.6 million in 2024.